Topics

MDSCs In Cancer Immunity And Therapy

Tumor Microenvironment Cancer Immunotherapy Chronic Inflammation

Myeloid-derived suppressor cells (MDSCs) are pathologically activated myeloid cells with potent immunosuppressive activity, and cancer studies place them among the major cellular barriers to antitumor immunity. The concept developed from observations that cancer, inflammation, and infection expand heterogeneous myeloid populations capable of suppressing T-cell responses. Standardized nomenclature later helped separate monocytic MDSCs and polymorphonuclear MDSCs from related monocytes and neutrophils, making MDSCs a defined focus in tumor immunology, cancer immune escape, prognosis, and immunotherapy resistance[1][2][3].

MDSCs suppress cancer immunity through coordinated metabolic, oxidative, cytokine, checkpoint, and trafficking mechanisms. They inhibit T cells and natural killer cells, use arginase, nitric oxide synthase, reactive oxygen species, and immunosuppressive cytokines to block immune activation, and accumulate in the tumor microenvironment under chronic inflammatory pressure. STAT3 regulates arginase-I in MDSCs from cancer patients, HIF-1α controls MDSC function and differentiation in the tumor microenvironment, and the STAT/IRF-8 axis regulates MDSC development, linking suppressive activity to transcriptional and metabolic control[1][4][5][6].

Therapeutic applications focus on reducing MDSC abundance, blocking recruitment, forcing differentiation, disabling suppressive function, and combining MDSC targeting with immune checkpoint blockade, adoptive cell therapy, radiotherapy, or chemotherapy. CXCR2 blockade disrupted MDSC tumor trafficking and enhanced anti-PD-1 efficacy in preclinical cancer models, all-trans retinoic acid reduced MDSCs and improved CAR T-cell therapy efficacy for sarcomas, and entinostat neutralized MDSCs while improving responses to PD-1 blockade in mouse tumor models. These studies position MDSCs as drug discovery targets and predictive biomarkers for immunotherapy-resistant tumors[7][8][9].

The central challenge is that MDSCs lack a single universal marker, differ across tumor type and tissue compartment, and overlap phenotypically with normal myeloid cells. Future research needs harmonized phenotyping, single-cell and spatial profiling, functional suppression assays, validated patient biomarkers, and therapies that selectively reprogram harmful MDSC states without broadly damaging protective myelopoiesis. The strongest clinical prospect is rational combination therapy that blocks MDSC recruitment or function while restoring T-cell and natural killer cell activity in the tumor microenvironment[2][3][10].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-13418 Dorsomorphin dihydrochloride
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
Organoid   AMPK   TGF-β Receptor   Autophagy  
Colorectal Cancer   Prostate Cancer   Ovarian Cancer   Pain   Digestive System Inflammation   Obesity  
819
HY-13418A Dorsomorphin
Dorsomorphin (BML-275) is a selective and ATP-competitive AMPK inhibitor (Ki=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
Organoid   AMPK   TGF-β Receptor   Autophagy  
819
HY-B0988 Deferoxamine mesylate
Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.
Autophagy   HIF/HIF Prolyl-Hydroxylase   Reactive Oxygen Species (ROS)   Apoptosis   Akt  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
452
HY-10431 SB-431542
SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways.
Organoid   TGF-β Receptor   Apoptosis  
Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   Digestive System Inflammation   Obesity   Lung Fibrosis  
323
HY-13818 Stattic
Stattic is a potent STAT3 inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727). Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice.
STAT   Apoptosis  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Digestive System Inflammation   Obesity  
322
HY-10201 Sorafenib
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
Raf   VEGFR   FLT3   Autophagy   Apoptosis   STAT   Akt   MMP   Cadherin   p38 MAPK   ERK   MEK   PI3K   PARP   Bcl-2 Family   Ephrin Receptor   PDGFR  
Gastric Cancer   Liver Cancer   Ovarian Cancer   Digestive System Inflammation   Small Cell Lung Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Metastatic Colorectal Cancer   Metastatic Prostate Cancer   Multiple Myeloma   Metastatic Pancreatic Cancer   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease   Obesity   Lung Fibrosis  
316
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
147
HY-10432 A 83-01
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
Organoid   TGF-β Receptor  
Cancer  
143
HY-B0069 Fludarabine
Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes.
Nucleoside Antimetabolite/Analog   DNA/RNA Synthesis   STAT   Apoptosis  
Lung Cancer   Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
119
HY-10231 PX-478
PX-478 is a multifunctional HIF-1α inhibitor with properties including radiosensitization, autophagy activation, and lipid accumulation inhibition. PX-478 also blocks hypoxia-induced VEGF production and regulates β-cell phenotypes under hypoxic conditions. PX-478 induces cell cycle arrest and DNA damage, restores autophagic function, reduces foam cell formation, and maintains glucose homeostasis. PX-478 is widely used in research on related diseases such as human tumors (e.g., prostate cancer), type 2 diabetes, and atherosclerosis.
HIF/HIF Prolyl-Hydroxylase   VEGFR   Autophagy  
Blood Disease   Type 1 Diabetes   Atherosclerosis  
115
HY-50912 Plerixafor octahydrochloride
Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC50 of 44 nM.
CXCR   HIV   Virus Protease  
Pancreatic Cancer   Viral Infection   Digestive System Inflammation   Glucose Metabolism   SARS-CoV-2 Infection   Lung Fibrosis   Rheumatoid Arthritis  
112
HY-10046 Plerixafor
Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM.
CXCR   HIV  
Pancreatic Cancer   Viral Infection   Digestive System Inflammation   Glucose Metabolism   SARS-CoV-2 Infection   Lung Fibrosis   Rheumatoid Arthritis  
112
HY-40354 Tofacitinib
Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury.
JAK   STAT   NF-κB  
Depression   Pulmonary Disease   Systemic Lupus Erythematosus   Liver Injury   Rheumatoid Arthritis  
103
HY-P1061A Colivelin TFA
Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro. Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury.
STAT   Amyloid-β   Apoptosis  
Neurological, Eye or Ear Disease  
102
HY-P1061 Colivelin
Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro. Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury
STAT   Amyloid-β  
Neurological, Eye or Ear Disease  
102
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Disease Focused Libraries

100
HY-12071 LDN193189
LDN193189 (DM-3189) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva.
Organoid   TGF-β Receptor  
Breast Cancer  
95
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-18729A L-NAME hydrochloride
L-NAME hydrochloride inhibits NOS with an IC50 of 70 μM. L-NAME is a precursor to NOS inhibitor L-NOARG which has an IC50 value of 1.4 μM. L-NAME hydrochloride requires hydrolysis of the methyl ester by cellular esterases to become a fully functional inhibitor. L-NAME hydrochloride can be used to induce hypertension and preeclampsia models.
NO Synthase  
Cancer   Neurological, Eye or Ear Disease   Viral Infection  
87
HY-15893 DMOG
DMOG (Dimethyloxallyl Glycine) is a cell permeable and competitive inhibitor of HIF-PH, which results in HIF-1α stabilisation and accmulation in vitro and in vivo. DMOG is an α-ketoglutarate analogue and inhibits α-KG-dependent hydroxylases. DMOG acts as a pro-angiogenic agent and plays a protective role in experimental model of colitis and diarrhoea via HIF-1 related signal. DMOG induces cell autophagy.
HIF/HIF Prolyl-Hydroxylase   Autophagy  
Breast Cancer   Prostate Cancer   Ovarian Cancer  
87
HY-14519 Methotrexate
Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
Antifolate   Dihydrofolate reductase (DHFR)   NO Synthase   COX   Interleukin Related  
Breast Cancer   Arthritis   Systemic Lupus Erythematosus   Psoriasis   Lung Fibrosis  
87
HY-L008 JAK/STAT Compound Library
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID). MCE provides 738 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Signaling Pathway Targeting Libraries

86
HY-L014 NF-κB Signaling Compound Library
Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development. MCE owns a unique collection of 1,801 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

Signaling Pathway Targeting Libraries

85
HY-L172 Immunopotentiator Compound Library
Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines. MCE designs a unique collection of 150 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.

Compound Characteristic Classified Libraries

83
HY-L174 Macrophage Related Compound Library
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance. MCE designs a unique collection of 276 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.

Compound Characteristic Classified Libraries

83
HY-L177 Antibody Inhibitor Library
Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases. MCE can provide 1,949 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

Compound Characteristic Classified Libraries

83
HY-L184 Anti-Gastric Cancer Compound Library
Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer. MCE designs a unique collection of 1,203 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Disease Focused Libraries

83
HY-L204 Lactic Acid Metabolic Compound Library
Lactic acid metabolism is one of the key metabolic pathways within living organisms. It plays a crucial role not only in cellular energy conversion but is also closely related to a variety of physiological and pathological processes. The production and clearance of lactic acid are important indicators of cellular metabolic balance, and its abnormal regulation may lead to conditions such as lactic acidosis, muscle fatigue, and hereditary metabolic diseases. Moreover, lactic acid is closely related to the malignancy of tumors and is considered a biomarker for malignant tumors and poor prognosis. Lactic acid can serve as a metabolic substrate to support the metabolic needs of tumor cells under hypoxic conditions, and it can also cause acidification of the tumor microenvironment, suppress immune cell function to promote immune evasion, and induce drug resistance in tumor cells. Currently, targeting lactic acid-lactylation and its related metabolic pathways has become a new research avenue for cancer treatment. In-depth exploration of the molecular mechanisms of lactic acid metabolism can help in screening lead compounds that regulate the lactic acid metabolism. MCE contains 582 small molecule compounds targeting enzymes involved in lactic acid metabolism. This library is of significant value for researching the role of lactate metabolism in the mechanisms of diseases.
83
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-L219 Antimicrobial Peptides Library
Antimicrobial Peptides (AMPs), also known as antimicrobial peptides or antibiotic peptides, are a class of polypeptides encoded by specific genes in various biological cells and induced by external stimuli. They exhibit broad-spectrum bioactivity against bacteria, fungi, viruses, protozoa, and even tumor cells. AMPs serve as crucial effector molecules in the host's innate immune system.Due to their wide antimicrobial spectrum, low toxicity to normal cells of higher animals, high safety profile, low tendency to induce resistance, and additional benefits such as immune enhancement and antioxidant effects, antimicrobial peptides hold significant promise in new drug development. MCE offers 58 types of antimicrobial peptides, which can be applied in high-throughput screening for research in anti-infection therapies, immunotherapy, anticancer drug development, and agricultural disease control.
83
HY-L227 Amino Acid Metabolite Compound Library
Amino acids are the fundamental components that sustain life activities, playing roles in ATP generation, promoting nucleotide synthesis, and maintaining cellular redox balance. Moreover, dysregulation of amino acid consumption is a significant potential regulatory mechanism leading to impaired anti-tumor immunity in immune cells. The normal functioning of immune cells relies on amino acid metabolic pathways to obtain energy and materials, and upon activation, they reprogram their metabolism to support growth, proliferation, and effector functions. Additionally, metabolic disorders of specific amino acids (such as branched-chain amino acids, glutamine, and arginine) can exacerbate mitochondrial dysfunction and oxidative stress, thereby promoting myocardial fibrosis and cardiac cell damage. Therefore, conducting research related to amino acid metabolism holds promise for discovering potential drugs for diseases related to cancer, immunity, and metabolism. MCE can provide 195 kinds of metabolites of amino acid metabolic pathways, which can be used for drug screening in various diseases such as cancer, immune disorders, metabolic diseases, mitochondrial-targeted diseases

Metabolism Focused Libraries

83
HY-L228 Lipid Metabolite Compound Library
Lipids are important energy storage substances in the human body. They are involved in the regulation of cell structure and function, as well as signaling pathways and gene expression. Abnormal lipid levels in tissues or their dysregulation can lead to various diseases. These include obesity, type 2 diabetes, non-alcoholic fatty liver disease, neurodegenerative diseases, infections, and cancer. Therefore, maintaining normal levels of lipid metabolism is critical to overall health. One of the key features of cancer is aberrant lipid metabolism. This includes alterations in lipid uptake, lipid desaturation, neolipogenesis, lipid droplets, and fatty acid oxidation in cancer cells. These changes all contribute to cellular survival in an ever-changing microenvironment. They do this by modulating feed-forward oncogenic signals and key oncogenic functions. Additionally, they affect oxidative stress, other types of stress, immune responses, and intercellular communication. Alterations in lipid metabolism have a strong impact on the properties of cancer stem cells. This includes aspects such as self-renewal, differentiation, invasion, metastasis, drug sensitivity, and resistance. Furthermore, these alterations also modulate T cell responses. MCE can offer 146 metabolites of lipid metabolism pathways, which can be used for drug screening in cancer, immune-based diseases, metabolic diseases, and other diseases.

Metabolism Focused Libraries

83
HY-L234 Nucleotide Metabolite Compound Library
Nucleotide metabolism is central to cancer aggressiveness, underpinning uncontrolled proliferation, chemotherapy resistance, immune evasion, and metastasis. It is transcriptionally regulated by oncogenes (e.g., MYC) and tumor suppressors (e.g., pRb). Nucleotide imbalance and nucleoside degradation further regulate cell state transitions, especially following replication stress. Additionally, secretion of nucleotides/nucleosides into the tumor microenvironment modulates immune responses and influences treatment efficacy. Therefore, nucleotide metabolites have roles in disease response and indication in cancer research, and can be utilized to develop cancer-related mechanisms and drugs. MCE can provide 83 metabolites produced by nucleotide metabolic pathways, which can be used for disease mechanism research and drug research.

Metabolism Focused Libraries

83
HY-L249 Lactylation Compound Library
Protein lactylation, an emerging post-translational modification identified in recent years, plays a critical role in linking cellular metabolic reprogramming, epigenetic regulation, and signaling networks. Based on a systematic framework encompassing lactate metabolism, lactylation, and downstream signaling pathways, this compound library comprehensively targets multiple regulatory layers, including histone modification enzymes (such as p300 and HDACs), key glycolytic enzymes (such as PKM2, LDHA, and GAPDH), transcriptional regulators (such as STAT3, HMGB1, and p53), as well as central signaling pathway nodes including HIF-1α, NF-κB, and PI3K-AKT-mTOR. This integrated design enables a comprehensive representation of the regulatory roles of lactylation across the “metabolism–epigenetics–signaling” axis. MCE has assembled a collection of 6,182 known bioactive compounds and potential functional molecules, making this library suitable for a wide range of applications, including high-throughput drug screening, inhibitor identification, and mechanistic studies. It can be used to systematically evaluate the functional roles of lactylation in biological processes such as tumor metabolism, immune regulation, and inflammatory responses, and to efficiently identify small-molecule candidates with regulatory potential, thereby facilitating the development of innovative therapeutics targeting the interplay between metabolism and epigenetic regulation.

Signaling Pathway Targeting Libraries

83
HY-L250 Lactic Acid Metabolite Compound Library
In the progression of various diseases, metabolic reprogramming has emerged as a key hallmark. Lactate, as an important metabolic signaling molecule, is widely involved in tumorigenesis, immune regulation, and inflammatory responses. Particularly within the tumor microenvironment, the abnormal accumulation of lactate not only affects cellular energy metabolism but also promotes disease progression by modulating immune cell functions and mediating protein lactylation, thereby participating in epigenetic regulation and signaling networks. Therefore, systematic investigation of lactate metabolic pathways and their associated metabolites is of great significance for understanding disease mechanisms and developing novel therapeutic strategies. The MCE lactic acid metabolite compound library contains 61 compounds and is constructed around key metabolic pathways involving lactate production, transport, and utilization. This library systematically includes core intermediates from glycolysis, the tricarboxylic acid (TCA) cycle, and the lactate cycle. Focusing on disease-associated metabolic reprogramming, it is suitable for research in oncology, inflammation, and metabolic disorders. The library can be used to elucidate the roles of lactate in tumor microenvironment regulation, immune evasion, and epigenetic modifications (such as protein lactylation). In addition, it provides high-quality small-molecule resources for drug screening, facilitating the discovery of potential modulators targeting key enzymes (such as LDH) or transporters (such as MCTs) involved in lactate metabolism.

Signaling Pathway Targeting Libraries

83
HY-13683 Mifepristone
Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC50s of 0.2 nM and 2.6 nM in in vitro assay.
Endogenous Metabolite   Progesterone Receptor   Glucocorticoid Receptor   NO Synthase   Autophagy  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Viral Infection   Depression   Pain  
80
HY-17412 Minocycline hydrochloride
Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.
Bacterial   Antibiotic   HIF/HIF Prolyl-Hydroxylase   Apoptosis   MDM-2/p53   Potassium Channel   Calcium Channel  
Metabolic or Endocrine Disease   Breast Cancer   Colorectal Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Bacterial Infection   Depression   Digestive System Inflammation   Cardiovascular Disease   SARS-CoV-2 Infection   Lung Fibrosis  
76
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-13226 Galunisertib
Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
TGF-β Receptor  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
74
HY-13426 Roxadustat
Roxadustat is an orally active hypoxia-inducible factor prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin.
HIF/HIF Prolyl-Hydroxylase   Ferroptosis  
Breast Cancer   Ovarian Cancer   SARS-CoV-2 Infection  
68
HY-18234A Leupeptin hemisulfate
Leupeptin hemisulfate is a broad-spectrum protease inhibitor. By inhibiting the activation of the PTEN/PI3K/Akt/NF-κB/ERK1/2/p38 signaling pathway, Leupeptin hemisulfate significantly reduces LPS-induced NO and ROS production, mitochondrial membrane potential hyperpolarization, phagocytic activity, pro-inflammatory cytokine release, and M1 polarization in mouse peritoneal macrophages, and reverses autophagic flux impairment. It also decreases Concanavalin A (HY-P2149)-induced proliferation index of mouse splenic lymphocytes and the Th1/IL-10 and Th2/IL-10 cytokine ratios, thereby modulating innate and adaptive immune responses. Leupeptin hemisulfate inhibits blood coagulation and tumorigenesis in mouse skin. Leupeptin hemisulfate can be used in research on chronic inflammatory diseases and skin tumorigenesis.

Source: Streptomyces roseus MB-26-AI

Ser/Thr Protease   Cathepsin   Autophagy   SARS-CoV   Atg8/LC3   NO Synthase   COX   p62   Arginase   PTEN   NF-κB   PI3K   Akt   p38 MAPK   ERK   Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   Respiratory Disease   Coronavirus Infection   Skin Disease  
68
HY-16711 SB225002
SB225002, a potent, selective and non-peptide CXCR2 antagonist, inhibits 125I-IL-8 binding to CXCR2 with an IC50 of 22 nM.
CXCR  
Metabolic or Endocrine Disease   Gastric Cancer   Digestive System Inflammation   Rheumatoid Arthritis  
66
HY-15251 Reparixin
Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC50s of 1 and 100 nM, respectively.
CXCR  
Metabolic or Endocrine Disease   Gastric Cancer   Pancreatic Cancer   Digestive System Inflammation   Rheumatoid Arthritis  
65
HY-N0193 Artesunate
Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).
STAT   Ferroptosis   Parasite   Virus Protease  
Inflammation or Immune System Disease   Lung Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Parasitic Infection   Metastatic Breast Cancer   Obesity  
43
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-15319 AMG 487
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC50s of 8.0 and 8.2 nM, respectively.
CXCR  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   Rheumatoid Arthritis  
40
HY-10230 Midostaurin
Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM. Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects.
PKC   VEGFR   c-Kit   NO Synthase   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Neurodegenerative Disease   Digestive System Inflammation   Lung Fibrosis  
39
HY-N0055 Chlorogenic acid
Chlorogenic acid is a major phenolic compound in Lonicera japonica Thunb. It is an orally active antioxidant activity, antibacterial, hepatoprotective, cardioprotective, anti-inflammatory, antipyretic, neuroprotective, anti-obesity, antiviral, anti-microbial, anti-hypertension compound.
HIF/HIF Prolyl-Hydroxylase   Reactive Oxygen Species (ROS)   Bacterial   Influenza Virus   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Breast Cancer   Ovarian Cancer   Viral Infection   Bacterial Infection   Cardiovascular Disease   Obesity  
38
HY-14944 Homoharringtonine
Homoharringtonine (Omacetaxine mepesuccinate;HHT) is a cytotoxic alkaloid with antitumor properties which acts by inhibiting translation elongation.
STAT  
Inflammation or Immune System Disease   Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Obesity  
37
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-117287 Deucravacitinib
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation. Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus.
JAK   STAT   Interleukin Related   IFNAR  
Systemic Lupus Erythematosus   Psoriasis   Inflammatory Bowel Disease  
36
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-10198 Navarixin
Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both CXCR1 and CXCR2, with Kd values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly.
CXCR  
Metabolic or Endocrine Disease   Prostate Cancer   Gastric Cancer   Digestive System Inflammation   SARS-CoV-2 Infection   Rheumatoid Arthritis  
32
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-N0455 L-Arginine
L-Arginine ((S)-(+)-Arginine) is the substrate for the endothelial nitric oxide synthase (eNOS) to generate NO. L-Arginine is transported into vascular smooth muscle cells by the cationic amino acid transporter family of proteins where it is metabolized to nitric oxide (NO), polyamines, or L-proline. L-Arginine is a potent vasodilator, and can be used to induce experimental acute pancreatitis.
NO Synthase   Endogenous Metabolite  
Prostate Cancer   Sepsis   Hypertension   Rheumatoid Arthritis  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-13848 Rugocrixan
AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human CX3CR1 receptor; antagonizes CX3CR1 and CXCR2 with Kis of 3.9 and 2800 nM, respectively.
CX3CR1   CXCR  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation  
26
HY-N0171A Beta-Sitosterol (purity>98%)
Beta-Sitosterol (purity>98%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc.
Bacterial   Apoptosis   Reactive Oxygen Species (ROS)   MDM-2/p53   Caspase   PARP   MMP   Bcl-2 Family   HIF/HIF Prolyl-Hydroxylase   TNF Receptor   Interleukin Related   NF-κB   mTOR   Lactate Dehydrogenase   CDK   Glutathione Peroxidase   SOD  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Bacterial Infection   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
24
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-13012 RepSox
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes.
Organoid   TGF-β Receptor  
Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   Glucose Metabolism   Obesity   Lung Fibrosis  
23
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-B0239 Chloramphenicol
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research.

Source: Streptomyces venezuelae

Antibiotic   Bacterial   HIF/HIF Prolyl-Hydroxylase   VEGFR   Autophagy   Apoptosis   Beclin1   JNK   Akt   MMP  
Infection   Respiratory Disease   Non-Small Cell Lung Cancer  
19
HY-N0143A Phlorizin dihydrate
Phlorizin (Floridzin) dihydrate is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin dihydrate promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin dihydrate reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin dihydrate induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin dihydrate also exhibits antibacterial, anti-inflammatory and neuroprotective activities.
SGLT   PI3K   Akt   GLUT   NF-κB   JAK   STAT   Caspase   Apoptosis   DNA/RNA Synthesis   mTOR   Bacterial  
Cancer   Neurological, Eye or Ear Disease   Bacterial Infection   Type 2 Diabetes  
18
HY-125840 Belzutifan
Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC).
HIF/HIF Prolyl-Hydroxylase  
Breast Cancer   Pancreatic Cancer   Ovarian Cancer  
16
HY-12273 DMH-1
DMH-1 is a selective BMP inhibitor. DMH-1 upregulates the expression of SOX1. DMH-1 increases cardiomyocyte progenitor cells and promotes the differentiation of mouse embryonic stem cells into cardiomyocytes. DMH-1 induces the differentiation of hiPSC-derived neural progenitor cells into β3-tubulin-positive neurons.
TGF-β Receptor   Organoid   Microtubule/Tubulin  
Neurological, Eye or Ear Disease   Heart Disease  
15
HY-146245 ODN 1826
ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma.
Toll-like Receptor (TLR)   Apoptosis   NO Synthase  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
14
HY-13406 TAK-779
TAK-779 is a potent and selective nonpeptide antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5, and effectively and selectively inhibits R5 HIV-1, with EC50 and EC90 of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.
CCR   HIV   CXCR  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Viral Infection   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
13
HY-N0390S1 L-Glutamine-13C5
L-Glutamine-13C5 is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
Isotope-Labeled Compounds   mGluR   Ferroptosis   Environmental Pollutants   Endogenous Metabolite   HIF/HIF Prolyl-Hydroxylase   mTOR   STAT   NF-κB  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
13
HY-101979A Numidargistat dihydrochloride
Numidargistat (CB-1158) dihydrochloride is a potent and orally active inhibitor of arginase, with IC50s of 86 nM and 296 nM for recombinant human arginase 1 and recombinant human arginase 2, respectively. Immuno-oncology agent.
Arginase  
Cancer  
12
HY-101979 Numidargistat
Numidargistat (CB-1158) is a potent and orally active inhibitor of arginase, with IC50s of 86 nM and 296 nM for recombinant human arginase 1 and recombinant human arginase 2, respectively. Immuno-oncology agent.
Arginase  
Cancer  
12
HY-19855 AZD-5069
AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.
CXCR  
Metabolic or Endocrine Disease   Prostate Cancer   Gastric Cancer   Pancreatic Cancer   Digestive System Inflammation   Rheumatoid Arthritis  
11
HY-W074143 Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride
Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride ([Ru(dpp)3]2+) is an electrochemiluminescent (ECL) probe and oxygen-sensitive sensor. Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride can be used to modify electrode surfaces for the detection of sulfates (S2O82-) and oxalates, based on electrochemical reactions that generate excited-state species, releasing photons through irreversible redox reactions. Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride utilizes the oxygen quenching of fluorescence mechanism, where fluorescence intensity reflects the metabolic rate of living microorganisms or oxygen levels within cells/tumors, allowing for real-time detection. Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride's main applications include microbial detection, antibacterial activity studies, and tumor microenvironment research.
Fluorescent Dye  
Cancer  
11
HY-100806 Kynurenic acid
Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.
iGluR   Endogenous Metabolite   Apoptosis   CXCR   GPR35  
Metabolic or Endocrine Disease   Colorectal Cancer   Depression   Digestive System Inflammation   Non-Small Cell Lung Cancer   Alzheimer's Disease   Parkinson's Disease  
11
HY-B1352 L-Ornithine
L-Ornithine ((S)-2,5-Diaminopentanoic acid) is a non-proteinogenic amino acid, is mainly used in urea cycle removing excess nitrogen in vivo. L-Ornithine shows nephroprotective.
Arginase   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease   SARS-CoV-2 Infection  
10
HY-16938 5'-Methylthioadenosine
5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
Endogenous Metabolite   Apoptosis   Parasite  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Parasitic Infection   Digestive System Inflammation  
10
HY-15775 Arginase inhibitor 1
Arginase inhibitor 1 is a potent inhibitor of human arginases I and II with IC50s of 223 and 509 nM, respectively.
Arginase  
Cancer  
8
HY-107632 GYY4137
GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocking the STAT3 pathway, demonstrating potent anticancer activity.
Apoptosis   STAT   NF-κB   NO Synthase   COX   TNF Receptor   Interleukin Related  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
8
HY-112885B nor-NOHA monoacetate
nor-NOHA monoacetate is a selective and reversible arginase inhibitor. nor-NOHA monoacetate induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA monoacetate has anti-leukemic activity. nor-NOHA monoacetate can used in study of endothelial dysfunction, immunosuppression and metabolism.
Arginase   Apoptosis  
Cancer   Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Cardiovascular Disease  
7
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-N1363 Royal Jelly acid
Royal Jelly Acid ((E)-Queen Bee Acid) is a major fatty acid found in royal jelly with oral bioavailability, exhibiting anti-inflammatory, anticancer, antimalarial, antiprotozoal, and neuroregulatory activities. Royal Jelly Acid can be used for research in various fields, including cancer, infections, immune inflammation, and neurological diseases.

Source: Royal Jelly

Endogenous Metabolite   NO Synthase   NF-κB   Parasite   IFNAR  
Cancer   Infection   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
6
HY-N0717 L-Valine
L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase.
Bacterial   Arginase   Akt  
Breast Cancer   Pancreatic Cancer   Bacterial Infection   Depression   Pain   Digestive System Inflammation   SARS-CoV-2 Infection  
6
HY-N2389 Formosanin C
Formosanin C is a diosgenin saponin with multiple biological activities. Formosanin C possesses multiple anti-tumor mechanisms, including inducing apoptosis and autophagy, blocking the cell cycle, inhibiting metastasis and inducing ferroptosis. Formosanin C can inhibit the NF-κB signaling pathway to exert anti-inflammatory effects, and enhance the activity of immune cells. Formosanin C exhibits the inhibiting effect against C. albicans. Formosanin C can be used for the study of anti-inflammation, antifungal anti and anti-cancer (including lung cancer, liver cancer, breast cancer and colorectal cancer, etc.).
Apoptosis   Autophagy   Ferroptosis   NF-κB   Fungal  
Inflammation or Immune System Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Fungal Infection   Multiple Myeloma  
5
HY-N2959 Brevilin A
Brevilin A is an orally active STAT3/JAK inhibitor (STAT3 IC50=?10.6 μM). Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy.
JAK   STAT   Apoptosis   Autophagy  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Digestive System Inflammation   Obesity   Rheumatoid Arthritis  
5
HY-P1956 HSA Protein
HSA Protein (Human serum albumin) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. HSA Protein exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. HSA Protein can block the inhibitory effect of GML on human T cells, providing protective function for T cells. HSA Protein is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, NF-κB, and peroxynitrite (ONOO-) in the vascular wall, contributing to the reduction of blood pressure.
This product is recombinant HSA Protein expressed in a microbial expression system.
NF-κB   NO Synthase  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
5
HY-W009722A Sodium diethylcarbamodithioate trihydrate, ACS, 99.0%
Sodium diethylcarbamodithioate trihydrate, ACS, 99.0% (Ditiocarb sodium trihydrate, ACS, 99.0%) is a copper reagent. The reaction with Cu2+ solution resulted in the formation of a complex, which increased the copper displacement precipitation rate. Sodium diethylcarbamodithioate trihydrate, ACS, 99.0% can reduce HIV infection and can be used in adjuvant immune research of high-risk breast cancer.
HIV   Biochemical Assay Reagents  
4
HY-N7674 Angoline
Angoline is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.
Interleukin Related   STAT  
Lung Cancer   Breast Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Digestive System Inflammation   Obesity  
4
HY-W009722 Sodium diethylcarbamodithioate trihydrate
Sodium diethylcarbamodithioate (Ditiocarb sodium) trihydrate is a copper reagent. The reaction with Cu2+ solution resulted in the formation of a complex, which increased the copper displacement precipitation rate. Sodium diethylcarbamodithioate trihydrate can reduce HIV infection and can be used in adjuvant immune research of high-risk breast cancer.
HIV   Biochemical Assay Reagents  
4
HY-W011303 Phytosphingosine
Phytosphingosine is a phospholipid with anti-inflammatory, antibacterial, and anti-cancer activities, which can induce apoptosis. Phytosphingosine is an immune regulator and can be used in the study of inflammatory skin diseases. Phytosphingosine is also an activator of GPR120 with an IC50 value of 33.4 μM and can be used in the study of type II diabetes.
Apoptosis   Endogenous Metabolite   Fungal   Free Fatty Acid Receptor  
Inflammation or Immune System Disease   Lung Cancer   Bacterial Infection   Fungal Infection   Glucose Metabolism  
4
HY-P80344 STAT3 Antibody (YA056)
STAT3 Antibody (YA056) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to STAT3.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

4
HY-18061 Ochromycinone
Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a STAT3 inhibitor. Ochromycinone can inhibits STAT3 DNA binding activity, STAT3 dimerization. Ochromycinone has anticancer and antimicrobial activity.

Source: Indonesian Streptomyces sp

Antibiotic   STAT   Bacterial  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Bacterial Infection   Obesity  
3
HY-B1180 Vinburnine
Vinburnine ((-)-Eburnamonine; (-)-Vincamone) is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.
Apoptosis   p38 MAPK  
Melanoma  
3
HY-101407 Nicotinamide N-oxide
Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the CXCR2 receptor.
Oxidative Phosphorylation   CXCR   Drug Metabolite   Endogenous Metabolite  
Metabolic or Endocrine Disease   Gastric Cancer   Digestive System Inflammation   Rheumatoid Arthritis  
3
HY-P99355 Bimagrumab
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness.

Species: Human

TGF-β Receptor  
Metabolic or Endocrine Disease  
3
HY-P4846 Ac-Pro-Gly-Pro-OH
Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and acts as a CXCR2 agonist. Ac-Pro-Gly-Pro-OH exerts bactericidal activity by generating hydrogen peroxide, inhibits pulmonary inflammation, and reduces immune cell apoptosis (apoptosis). Ac-Pro-Gly-Pro-OH promotes the production of IFN-γ and inhibits the production of TNF-α and IL-6 in leukocytes. Ac-Pro-Gly-Pro-OH increases the survival rate of mice in sepsis models, enhances the bactericidal activity of neutrophils, acts as a neutrophil chemoattractant, induces neutrophil polarization, and regulates inflammatory and repair processes. Ac-Pro-Gly-Pro-OH induces chronic inflammation and tissue remodeling through sustained action. Ac-Pro-Gly-Pro-OH is released via alkaline hydrolysis of corneal proteins in alkali-injured eyes, thereby driving the early infiltration of neutrophils into the cornea. Ac-Pro-Gly-Pro-OH is applicable to research related to sepsis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis obliterans syndrome, severe asthma, idiopathic pulmonary fibrosis, and corneal ulcer.
CXCR   Apoptosis   IFNAR   TNF Receptor   Interleukin Related  
Infection   Allergy  
2
HY-N2353 Arabinose
Arabinose is a pentose sugar commonly found in plants. Arabinose alleviates immune dysregulation and inflammation by promoting balanced immune responses and reducing inflammation. Arabinose induces cytotoxicity, autophagy (Autophagy), and cell cycle arrest in breast cancer cells through the p38-MAPK signaling pathway. Arabinose activates the ACSS2-PPARγ/TFEB-AMPK axis in neuroblastoma cells, thereby exerting neuromodulatory/antidepressant effects. Arabinose can also be used as an intermediate in compound synthesis. Arabinose may be applied in research related to immune inflammation, depression, breast cancer, and other diseases.
Environmental Pollutants   Endogenous Metabolite  
Inflammation or Immune System Disease   Breast Cancer   Depression  
2
HY-N6985 Baccatin III
Baccatin III is an orally available, selective inhibitor of the TGF-β1 signaling pathway and myeloid-derived suppressor cell (MDSC) activation. Baccatin III targets the AKT/STAT6 and Smad2/3 pathways, blocking TGF-β1-induced fibroblast differentiation and MDSC-mediated immunosuppression. Baccatin III exerts anti-inflammatory and anti-fibrotic effects by inhibiting macrophage activation and extracellular matrix deposition, and shows potential in the treatment of pulmonary fibrosis and cancer in terms of regulating the tumor immune microenvironment.
Others  
Breast Cancer   Lung Fibrosis  
2
HY-P1181 Pam2CSK4
Pam2CSK4 is a TLR2 agonist. Pam2CSK4 induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis.
Toll-like Receptor (TLR)   NO Synthase   IKK   Akt   PKC   NF-κB   p38 MAPK   Interleukin Related  
Leukemia/Lymphoma/Myeloma   Cancer Immunology   Immunotherapy for Melanoma   Influenza Virus Infection   Atherosclerosis and Inflammation   Heart Failure  
1
HY-15306S Eltrombopag-13C4
Eltrombopag-13C4 (SB-497115-13C4) is 13C-labeled Eltrombopag. Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells.
Thrombopoietin Receptor   Bacterial   Apoptosis  
Cancer   Blood or Cardio-cerebrovascular Disease   Staphylococcus Aureus Infection  
1
HY-P2282 APTSTAT3-9R
APTSTAT3-9R, a specific STAT3-binding peptide, inhibits STAT3 activation and downstream signaling by specifically blocking STAT3 phosphorylation. APTSTAT3-9R exerts antiproliferative effects and antitumor activity.
STAT  
1
HY-P991447 Anti-VSIR/VISTA Antibody (SG7)
Anti-VSIR/VISTA Antibody (SG7) is an antibody targeting VISTA, with a Kd of 0.14 nM for human VISTA and 1 nM for mouse VISTA. Anti-VSIR/VISTA Antibody (SG7) blocks the function of VISTA, prevents VISTA from binding to T cells, restores suppressed T cell activation, and blocks the interactions between VISTA and PSGL-1 as well as VSIG3. Anti-VSIR/VISTA Antibody (SG7) slows tumor growth, reduces PMN-MDSCs, and increases the numbers of CD4+ and CD8+ T cells in the tumor microenvironment. Anti-VSIR/VISTA Antibody (SG7) can be used in studies related to melanoma, colon cancer, and breast cancer.

Species: Human

VISTA  
Breast Cancer   Colorectal Cancer   Melanoma  
1
HY-P99732 Minretumomab
Minretumomab (CC-49) is a murine monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab is used in cancer and immunity research.

Species: Human

Mucin  
Cancer  
1
HY-P3448 Certepetide
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
Integrin   Complement System  
1
HY-16938S1 5'-Methylthioadenosine-d3
5'-Methylthioadenosine-d3 is the deuterium labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
Apoptosis   Parasite   Endogenous Metabolite  
Inflammation or Immune System Disease  
1
HY-P99039 Oleclumab
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity.

Species: Human

CD73  
Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99210 Olokizumab
Olokizumab (CDP 6038) is a humanized monoclonal antibody that targets interleukin-6 (IL-6). Olokizumab inhibits IL-6-induced STAT-3 phosphorylation. Olokizumab is used in the study of arthritis.

Species: Human

Interleukin Related   STAT  
Rheumatoid Arthritis  
1
HY-P99742 Mitazalimab
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.

Species: Human

TNF Receptor  
Cancer  
1
HY-W591424 m-PEG2000-NHS ester
m-PEG2000-NHS ester (mPEG2000-SC) is a reagent with both cell adhesion inhibition and peptide conjugation functions. The NHS ester group of m-PEG2000-NHS ester forms stable amide bonds with primary amine-containing molecules (e.g., the N-terminus of MMP-2-cleavable octapeptide) to generate mPEG-peptide intermediates for liposome surface modification. When m-PEG2000-NHS ester is immobilized on a cystamine-modified gold surface, it can construct an in vitro model for cell adhesion kinetic studies, and higher PEG density and thicker layers correlate with lower cell adhesion rates. m-PEG2000-NHS ester can synthesize MMP-2-responsive PEGylated lipid conjugates to achieve MMP-triggered dePEGylation in the tumor microenvironment. m-PEG2000-NHS ester can be used in studies related to colon cancer and other conditions.
Biochemical Assay Reagents   MMP  
Colorectal Cancer  
1
HY-N0819 Raddeanin A
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.
Apoptosis   PI3K   Akt   ERK   mTOR   Wnt   β-catenin   Wee1   JNK   VEGFR   CDK  
Colorectal Cancer   Leukemia/Lymphoma/Myeloma   Cancer Immunology   Digestive System Inflammation   Non-Small Cell Lung Cancer   Immunotherapy for Melanoma   Alzheimer's Disease  
1
HY-P1181A Pam2CSK4 TFA
Pam2CSK4 TFA is a TLR2 agonist. Pam2CSK4 TFA induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 TFA activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 TFA expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 TFA acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 TFA can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis.
Toll-like Receptor (TLR)   NO Synthase   IKK   Akt   PKC   NF-κB   p38 MAPK   Interleukin Related  
Leukemia/Lymphoma/Myeloma   Cancer Immunology   Immunotherapy for Melanoma   Influenza Virus Infection   Atherosclerosis and Inflammation   Heart Failure  
1
HY-125474 Carrageenan
Carrageenan is an antiviral and anticancer agent. Carrageenan inhibits herpes simplex virus (HSV), HIV, and hepatitis A virus (HAV) by directly binding to the viral capsid to block the attachment of viruses such as HPV to HSPG factors on the cell surface. Carrageenan delays and arrests cell cycle progression, exhibits cytotoxicity against HeLa cancer cells, and can be applied to studies related to cervical cancer, genital warts, hepatitis A, and other conditions. Carrageenan also induces acute non-immune inflammation, triggers a three-phase inflammatory response involving the release of multiple proinflammatory mediators, and causes persistent edema, hyperalgesia, and neutrophil recruitment in mice.
Environmental Pollutants   HSV   HIV  
Cervical Cancer   HIV Infection   Hepatitis Virus Infection   HSV Infection  
1
HY-19548A BEC hydrochloride
BEC hydrochloride is a slow-binding and competitive Arginase II inhibitor with Ki of 0.31 μM and 30 nM at pH 7.5 and pH 9.5, respectively.
Arginase  
Cancer   Metabolic or Endocrine Disease  
1
HY-112868B ABH hydrochloride
ABH (hydrochloride) is an orally active arginase inhibitor (Ki = 8.5 nM). ABH hydrochloride promotes NO production and reduces the expression of inflammatory response-related molecules (ICAM-1, VCAM-1, MCP-1). ABH hydrochloride improves erectile function, reduces lung damage, promotes wound healing, reduces arterial blood pressure, and improves vascular fibrosis.
Arginase   NO Synthase   Integrin  
Cancer   Inflammation or Immune System Disease   Cardiovascular Disease   Glucose Metabolism  
1
HY-I1124 L-Valine-d8
L-Valine-d8 is a deuterated form of L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase.
Isotope-Labeled Compounds   Arginase   Akt   Bacterial  
Infection  
1
HY-143712 Allolithocholic acid
Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC50 = 2.7 μM) and RORγt inverse agonist (IC50 = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease.
Drug Metabolite   G protein-coupled Bile Acid Receptor 1   ROR  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P71833 Arginase-1/ARG1 Protein, Mouse (P.pastoris, His)
Arginase-1 (ARG1) plays a key role in the urea cycle, converting L-arginine into urea and L-ornithine. This cycle maintains L-arginine homeostasis, which is critical for nitric oxide synthase to compete for arginine. Arginase-1/ARG1 Protein, Mouse (P.pastoris, His) is the recombinant mouse-derived Arginase-1/ARG1 protein, expressed by P. pastoris , with N-6*His labeled tag.

Species: Mouse; Source: P. pastoris

Enzymes & Regulators Hydrolases (EC 3)

1
HY-P7541A Arginase-1/ARG1 Protein, Human (N-His)
Arginase-1 (ARG1) protein, crucial in the urea cycle, converts L-arginine to urea and L-ornithine. ARG1 also regulates L-arginine levels outside the liver, impacting immune responses. ARG1's release by granulocytes suppresses T cell and NK cell functions. In ILC2s, ARG1 promotes lung inflammation. However, ARG1's role in human monocytic/macrophage/dendritic cells is unclear. Arginase-1/ARG1 Protein, Human (N-His) is the recombinant human-derived Arginase-1/ARG1 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Hydrolases (EC 3)

1
HY-P80857 Phospho-STAT3 (Tyr705) Antibody
Phospho-STAT3 (Tyr705) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-STAT3 (Tyr705).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Modification Specific Antibodies Primary Antibodies

1
HY-P80281 Phospho-STAT3 (Ser727) Antibody (YA147)
Phospho-STAT3 (Ser727) Antibody (YA147) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-STAT3 (Ser727).

Host: Rabbit; Reactivity: Human, Rat, Mouse

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

1
HY-P80902 STAT3 Antibody (YA666)
STAT3 Antibody (YA666) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to STAT3.

Host: Mouse; Reactivity: Human, Rat, Mouse

Monoclonal Antibodies Primary Antibodies

1
HY-B0667S1 Balsalazide-d4
Balsalazide-d4 is deuterium labeled Balsalazide. Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.
Isotope-Labeled Compounds   Interleukin Related   STAT  
Cancer   Inflammation or Immune System Disease  
/
HY-12292G IM-12 (GMP)
IM-12 GMP is IM-12 (HY-12292) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IM-12 is an orally active anti-inflammatory agent that targets and inhibits the NF-κB and STAT3 signaling pathways. IM-12 activates the Wnt signaling pathway and promotes the nuclear translocation of β-catenin by inhibiting GSK3β, while also blocking the tyrosine kinase activity of p210BCR/ABL. IM-12 reduces the levels of IL-6, IL-17, NO, prostaglandin E2, iNOS and COX-2, and induces ER stress, Ca2+ release, autophagy and apoptosis. IM-12 is heat-sensitive and does not induce autophagy in IM-resistant p210BCR/ABLT315I mutant cells. IM-12 is also a component of the 5iLA medium used for naive pluripotent stem cell research. IM-12 has been applied in studies related to carrageenan (HY-125474)-induced hind paw edema, TNBS-induced colitis, and acute and chronic myeloid leukemia.
NF-κB   STAT   GSK-3   β-catenin   Bcr-Abl  
Leukemia/Lymphoma/Myeloma  
/
HY-131384 8,11,14-Eicosatriynoic acid
8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX)and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μMand 25 μM, respectively. In addition, 8,11,14-Eicosatriynoic Acid inhibits the action of slow-reacting substances of allergic reactions, with IC50 value of 10 μM. Lipoxygenase is widely found in fungi, plants and animals. 12-LO involves in many important disease states and may play a role in oxidative glutamate toxicity. COX enzymes play complex roles in human physiology and pathology involving the neuronal, immune, renal, cardiovascular, gastrointestinal and reproductive systems. COX enzymes are blocked by aspirin and a variety of other NSAIDs, which makes them clinically important. 5-LO involves in cancer pathology. It is expressed by a variety of cancer cells, including colon, lung, breast, and prostate cancers, and promotes cancer cell growth and neovascularization. 8,11,14-Eicosatriynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
COX  
/
HY-B0497G Niclosamide (GMP)
Niclosamide (GMP) is Niclosamide (HY-B0497) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells.
Antibiotic   STAT   Parasite  
/
HY-N6985R Baccatin III (Standard)
Baccatin III (Standard) is the analytical standard of Baccatin III. This product is intended for research and analytical applications. Baccatin III is a natural product isolated from Pacific yew tree and related species. Baccatin III reduces tumor progression by inhibiting the accumulation and suppressive function of MDSCs.
Reference Standards   Others  
Cancer  
/
HY-P991370 SBT-100 (His Tag)
SBT-100 (His Tag) is a human monoclonal antibody (mAb) targeting STAT3. SBT-100 (His Tag) inhibits IL-6-mediated P-STAT3 nuclear translocation in HEp-2 and PANC-1 cells. SBT-100 (His Tag) has tumor growth inhibitory effects on MDA-MB-231.

Species: Human

STAT  
Cancer  
/
HY-P99723 Manelimab
Manelimab (BCD-135) is a monoclonal antibody targeting PD-L1 with PD-L1 inhibitory activity. Manelimab blocks the interaction between PD-L1 and PD-1 to abrogate the immunosuppressive signals of T cells in the tumor microenvironment. Manelimab is applicable for tumor-related research.

Species: Human

PD-1/PD-L1  
Cancer  
/
HY-P6424S LGADMEDVCG-Arg(13C6,15N4) TFA
LGADMEDVCG-Arg(13C6, 15N4) TFA is a peptide containing 13C6 and 15N4 labeled Arg.
Isotope-Labeled Compounds  
/
HY-16938R 5'-Methylthioadenosine (Standard)
5'-Methylthioadenosine (Standard) is the analytical standard of 5'-Methylthioadenosine. This product is intended for research and analytical applications. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis[1]. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2].
Reference Standards   Endogenous Metabolite   Apoptosis   Parasite  
Cancer   Metabolic or Endocrine Disease  
/
HY-P11052 A8 peptide
A8 peptide is a Hsp72 antagonist. A8 peptide inhibits tumor progression and metastasis as well as enhances the cancer cells' sensitivity to apoptosis induced by chemotherapeutic agents (such as Cisplatin (HY-17394)) by blocking the Hsp72-TLR2 interaction and the subsequent activation of MDSCs. A8 peptide can be used for cancers research.
HSP  
/
HY-P11405 [D-Arg1,D-Trp5,7,9,Leu11]-Substance P
[D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P is a potent inhibitor of cell growth in small cell lung cancer (SCLC). [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P is also a neuropeptide antagonist, capable of blocking colony formation stimulated by various neuropeptides (including vasopressin and bradykinin). [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P inhibits the mobilization of Ca2+ and the activation of mitogen-activated protein kinases induced by vasopressin or bradykinin. [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P inhibits the growth of H-69 xenograft tumors in nude mice.
Neurotensin Receptor  
Neurological, Eye or Ear Disease   Small Cell Lung Cancer  
/
HY-P10101 APT STAT3, scrambled
APT STAT3, scrambled (APTscr), a control peptide of STAT3-specific aptide (APTSTAT3), does not bind STAT3. APT STAT3, scrambled contains the same trpzip scaffold but with a scrambled sequence in the target-binding site.
STAT  
/
HY-N20682 1-Hydroxy-4αH-1,10-secoeudesma-5(6),10(14),11(13)-trien-12,8β-olide
1-Hydroxy-4αH-1,10-secoeudesma-5(6),10(14),11(13)-trien-12,8β-olide is a neuroprotective agent. 1-Hydroxy-4αH-1,10-secoeudesma-5(6),10(14),11(13)-trien-12,8β-olide reduces the protein expression levels of iNOS and COX-2, blocks the DNA-binding activity of NF-κB, and inhibits nitric oxide production. 1-Hydroxy-4αH-1,10-secoeudesma-5(6),10(14),11(13)-trien-12,8β-olide promotes the polarization of microglia to the M2 phenotype by inducing the production of Arg-1, and alleviates cell damage induced by H2O2 and 6-Hydroxydopamine (HY-B1081).
NO Synthase   COX   NF-κB   Arginase  
/
HY-N17494 Crispene E
Crispene E is a STAT3 inhibitor with an IC50 of 10.27 μM against STAT3 dimerization. Crispene E exerts specific cytotoxicity against STAT3-dependent MDA-MB-231 breast cancer cells. Crispene E is applicable to research related to breast cancer.
STAT   Bcl-2 Family   CDK  
Breast Cancer  
/
HY-P991274 BMS-986010
BMS-986010 is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). BMS-986010 reduces IL-23-induced STAT3 phosphorylation and inhibits Th17 cell differentiation and the release of proinflammatory cytokines (such as IL-17 and TNF-α). BMS-986010 is promising for research of autoimmune diseases such as psoriasis and Crohn's disease.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease  
/
HY-N0390G L-Glutamine (GMP)
L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
mTOR   NF-κB   STAT   HIF/HIF Prolyl-Hydroxylase  
Inflammation or Immune System Disease   Ischemic Stroke   Osteoporosis   Osteoarthritis  
/
HY-P991746 Anti-Mouse CXCR2 Antibody (Cx2Mab-1)
Anti-Mouse CXCR2 Antibody (Cx2Mab-1) reacts with mouse CXCR2 targeting the N-terminal extracellular domain of CXCR2. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682).

Species: Mouse

CXCR  
Cancer  
/
HY-143712R Allolithocholic acid (Standard)
Allolithocholic acid (Standard) is the analytical standard of Allolithocholic acid (HY-143712). This product is intended for research and analytical applications. Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC50 = 2.7 μM) and RORγt inverse agonist (IC50 = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease.
Reference Standards   Drug Metabolite   G protein-coupled Bile Acid Receptor 1   ROR  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-163426S AFFGHYLYEVAR-(Arg-13C6,15N4)
AFFGHYLYEVAR-(Arg-13C6,15N4) is 13C and 15N labeled AFFGHYLYEVAR-(Arg).
Isotope-Labeled Compounds  
/
HY-P992344 DNP002
DNP002 is a humanized IgG1 monoclonal antibody targeting tumor-associated CEACAM6. DNP002 binds to CEACAM1, CEACAM5 and CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6 on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001).

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-113261S1 Oleoylcarnitine-13C,d3
Oleoylcarnitine-13C,d3 is the deuterium and 13C-labeled Oleoylcarnitine (HY-113261). Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation.
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease  
/
HY-N0193S Artesunate-d3
Artesunate-d3 is the deuterium labeled Artesunate. Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).
STAT   Ferroptosis   Parasite   Virus Protease  
Cancer  
/
HY-P1610 Asudemotide
Asudemotide (S-588410) is a peptide of human DEP domain-containing protein 1A. Asudemotide is an immunostimulant. Asudemotide has a sequence of H-Glu-Tyr-Tyr-Glu-Leu-Phe-Val-Asn-Ile-OH. Asudemotide induces a tumor immune response in esophageal cancer. .
PD-1/PD-L1  
/
HY-B1436S Nifuroxazide-d4
Nifuroxazide-d4 is the deuterium labeled Nifuroxazide. Nifuroxazide is an effective inhibitor of STAT3, also exerts potent anti-tumor and anti-metastasis activity.
STAT   Bacterial   Antibiotic  
Cancer   Infection  
/
HY-P10096 STAT3-IN-22, negative control
STAT3-IN-22, negative control (PYLKTK) is a peptide that serves as a control peptide for phosphotyrosine.
Others  
/
HY-N0193S1 Artesunate-d4
Artesunate-d4 is deuterium labeled Artesunate. Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).
Isotope-Labeled Compounds   STAT   Ferroptosis   Parasite   Virus Protease  
Cancer  
/
HY-W251598I Sodium bicarbonate, meets analytical specification of Ph. Eur., BP, USP, FCC, E500
Sodium bicarbonate, meets analytical specification of Ph. Eur., BP, USP, FCC, E500 is an inorganic salt that is neutral to slightly alkaline and easily decomposes when exposed to moisture in the air. Sodium bicarbonate can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, medicine, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
Bacterial   NO Synthase  
Gastric Disease   Triple-Negative Breast Cancer  
/
HY-P6421S LGPLVEQG-Arg(13C6,15N4) TFA
LGPLVEQG-Arg(13C6, 15N4) TFA is a peptide containing 13C6 and 15N4 labeled Arg.
Isotope-Labeled Compounds  
/
HY-P10427 DV1
DV1 is a CXCR4 inhibitor with anti-proteolytic properties that specifically blocks the binding of SDF-1α to its receptor. DV1 inhibits the migration of breast cancer cells and enables the targeted delivery of avidin-PLGA nanoparticles to CXCR4-expressing cancer cells. DV1 not only effectively suppresses the progression of metastatic breast cancer in mouse models, but also preferentially accumulates in brain tumor tissues rather than normal brain tissues, showing potential for inhibiting intracranial tumor metastasis. As a humoral immune stimulant, DV1 induces the production of specific IgG, neutralizing antibodies and cellular immune responses, thereby providing the host with protection against lethal challenges. DV1 has been applied to studies on CXCR4-expressing cancers, glioblastoma, dengue fever and other related diseases.
CXCR   Dengue Virus  
Immunomodulation   Metastatic Breast Cancer   Hepatitis B Virus Related Hepatocellular Carcinoma   Glioblastoma  
/
HY-P10113 STAT3-IN-23
STAT3-IN-23 (PY*LKTK) is a potent STAT3 inhibitor.
STAT  
Cancer  
/
HY-16938S2 5'-Methylthioadenosine-13C5
5'-Methylthioadenosine-13C5 (5'-(Methylthio)-5'-deoxyadenosine-13C5) is the 13C--labeled 5'-Methylthioadenosine (HY-16938). 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   Parasite  
Cancer   Metabolic or Endocrine Disease  
/
HY-P990038 Eurestobart
Eurestobart (ES002023) is a recombinant human IgG1 antibody against CD39. Eurestobart restores antitumor immunity by stabilizing the pro-inflammatory extracellular ATP (eATP) and interfering with synthesis of the immunosuppressive adenosine within the tumor microenvironment (TME). Eurestobart is used in the research of locally advanced and metastatic solid tumors.

Species: Human

NTPDase  
Neurological, Eye or Ear Disease  
/
HY-P11798 P-Selectin binding peptide
P‑Selectin binding peptide is a short peptide that specifically targets P‑selectin. P‑Selectin binding peptide binds with high affinity to P‑selectin, which is highly expressed on activated platelets, inflamed endothelium, and in the tumor microenvironment. P‑Selectin binding peptide is used for precise targeted delivery and intervention in inflammation, thrombosis, and tumors.
P-selectin  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P992305 Anti-STAT3 Antibody
Anti-STAT3 Antibody is a monoclonal antibody that targets STAT3. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-STAT3 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

STAT  
Inflammation or Immune System Disease  
/
HY-P992035 AMY109
AMY109 is an anti-human interleukin-8 (IL-8) monoclonal antibody, with a Ka of 36.8 pM for human IL-8, and a Ka of 380 pM for cynomolgus monkey IL-8. AMY109 binds to human and cynomolgus monkey IL-8 in a pH-dependent manner, inhibits IL-8-mediated activation of CXCR1 and CXCR2, and blocks the downstream biological activities of IL-8. AMY109 inhibits neutrophil recruitment to endometriotic lesions and suppresses monocyte chemoattractant protein-1 production by neutrophils. AMY109 is applicable to research related to endometriosis.

Species: Human

Interleukin Related  
Endometriosis  
/
HY-N2573 Corydalmine
Corydalmine (L-Corydalmine) inhibits spore germination of some plant pathogenic as well as saprophytic fungi. Corydalmine acts as an oral analgesic agent, exhibiting potent analgesic activity. Corydalmine alleviates Vincristine-induced neuropathic pain in mice by inhibiting an NF-κB-dependent CXCL1/CXCR2 signaling pathway.
Fungal   CXCR  
Infection   Neurological, Eye or Ear Disease  
/
HY-W701397 Nicotinamide N-oxide-d4
Nicotinamide N-oxide-d4 is the deuterium labeled Nicotinamide N-oxide (HY-101407). Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the CXCR2 receptor.
Isotope-Labeled Compounds   Endogenous Metabolite   Drug Metabolite   CXCR   Oxidative Phosphorylation  
Inflammation or Immune System Disease  
/
HY-D145729F FAM-Danvatirsen
FAM-Danvatirsen is a FAM-labeled Danvatirsen (HY-145729). Danvatirsen is an antisense oligonucleotide targeting STAT3 that can be used in the study of cancer.
Fluorescent Dye   STAT  
Cancer  
/
HY-143712S1 Allolithocholic Acid-d4
Allolithocholic Acid-d4 (3α-hydoxy-5α-Cholaoic Acid-d4, allo-LCA-d4) is deuterium labeled Allolithocholic acid (HY-143712). Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC50 = 2.7 μM) and RORγt inverse agonist (IC50 = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease.
Isotope-Labeled Compounds   Drug Metabolite   G protein-coupled Bile Acid Receptor 1   ROR  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N20707 Castalagin
Castalagin is an orally active natural product with multiple biological activities including antibacterial activity against bacteria and anti-leishmanial activity against Leishmania aethiopica. Castalagin exhibits inhibitory activity against PARP1 and DNA topoisomerase II, with an IC50 of 0.86 μM for bovine PARP1. Castalagin reduces poly (ADP-ribosyl) ation modification in cells. Castalagin binds to the cell envelope of Ruminococcus bromii, increases the ratio of CD8+/FOXP3+CD4+ T cells in the tumor microenvironment, and acts as a prebiotic to enhance the activity of anti-PD-1 therapy. Castalagin induces morphological changes in Leishmania aethiopica promastigotes and inhibits their proliferation. Castalagin inhibits PBP2a-mediated peptidoglycan layer stabilization, disrupts bacterial peptidoglycan assembly, and inhibits and disintegrates bacterial biofilms. Castalagin can be used in research related to diseases such as cancer, leishmaniasis, and bacterial infections.
PARP   Topoisomerase   Penicillin-binding protein (PBP)   PD-1/PD-L1   Bacterial   Parasite  
Cancer   Bacterial Infection   Leishmania Infection  
/
HY-P10295 p53 (232-240)
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system.
MDM-2/p53  
/
HY-P6423S CLAVYQAGA-Arg(13C6,15N4) TFA
CLAVYQAGA-Arg(13C6, 15N4) TFA is a peptide containing 13C6 and 15N4 labeled Arg.
Isotope-Labeled Compounds  
/
HY-W753201 5'-Methylthioadenosine-13C
5'-Methylthioadenosine-13C (5'-(Methylthio)-5'-deoxyadenosine-13C) is the 13C-labeled 5'-Methylthioadenosine (HY-16938). 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
Isotope-Labeled Compounds   Endogenous Metabolite   Parasite   Apoptosis  
/
HY-P11882 SYN1436
SYN1436 is a selective human neonatal Fc receptor (hFcRn) antagonist with an IC50 of 2.4 nM. SYN1436 binds to hFcRn and inhibits hFcRn-hIgG interaction. SYN1436 can be used for the research of autoimmune diseases.
Fc Receptor (FcR)  
Autoimmune Disease  
/
HY-P991870 Anti-Arginase-1 Antibody
Anti-Arginase-1 Antibody is an antibody against human Arginase-1/ARG1. Recommend Isotype Controls:?Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Arginase  
Cancer  
/
HY-159771 FAP6-19
FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
FAP  
Cancer  
/
HY-W011303S Phytosphingosine-d7
Phytosphingosine-d7 (4-Hydroxysphinganine-d7) is deuterium labeled Phytosphingosine. Phytosphingosine is a phospholipid with anti-inflammatory, antibacterial, and anti-cancer activities, which can induce apoptosis. Phytosphingosine is an immune regulator and can be used in the study of inflammatory skin diseases. Phytosphingosine is also an activator of GPR120 with an IC50 value of 33.4 μM and can be used in the study of type II diabetes.
Isotope-Labeled Compounds   Apoptosis   Free Fatty Acid Receptor   Fungal   Endogenous Metabolite  
Cancer   Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-W251598J Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard
Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard is an inorganic salt. Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard is widely used in the fields of food, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
Bacterial   NO Synthase  
Cancer   Gastric Disease  
/
HY-P3881 (D-Arg1,D-Pro2,D-Phe7,D-His9)-Substance P
(D-Arg1,D-Pro2,D-Phe7,D-His9)-Substance P is a selective NK1 receptor antagonist.
Neurokinin Receptor  
Neurological, Eye or Ear Disease  
/
HY-D3181 CyGbPF
CyGbPF is a granzyme B-specific near-infrared fluorescent probe. CyGbPF can be cleaved by granzyme B to remove the peptide cage group, restoring near-infrared fluorescence. CyGbPF passively accumulates in mouse tumors, and its activated fluorescence correlates with granzyme B expression, CD8+ cytotoxic T lymphocyte populations, and CD4+ helper T lymphocyte populations in tumor tissues. CyGbPF is efficiently cleared by the kidneys, enabling the assessment of immune activation via optical urine analysis. CyGbPF allows real-time non-invasive evaluation of cancer immunotherapeutic efficacy in living animals. CyGbPF can be used in research on cancers such as breast cancer. Excitation wavelength/emission wavelength: approximately 658 nm/approximately 717 nm.
Fluorescent Dye   Caspase  
Breast Cancer  
/
HY-P3225 (D-Arg1,D-Pro2,D-Trp7,9,L-Leu11)-Substance P acetate
(D-Arg1,D-Pro2,D-Trp7,9,L-Leu11)-Substance P (acetate) is an antagonist for Substance P (HY-P0201) and Bombesin (HY-P0195) that has effects on ocular inflammatory responses to antidromic trigeminal nerve stimulation.
Bombesin Receptor   Neurokinin Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-121151S (±)-Methotrexate-d3
(±)-Methotrexate-d3 ((±)-Amethopterin-d3; (±)-CL14377-d3; (±)-WR19039-d3) is the deuterated-labeled (±)-Methotrexate (HY-121151). (±)-Methotrexate is the racemate of Methotrexate (HY-14519). Methotrexate is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
Isotope-Labeled Compounds   Antifolate   Dihydrofolate reductase (DHFR)   NO Synthase   COX   Interleukin Related   Drug Isomer  
Breast Cancer   Arthritis   Systemic Lupus Erythematosus   Psoriasis   Lung Fibrosis  
/
HY-D2310 CXCR2 Probe 1
CXCR2 Probe 1 (Compound 16b) is a selective ligand for CXCR2 and is a radiotracer for PET imaging of neutrophils in inflammatory diseases.
CXCR  
Inflammation or Immune System Disease  
/
HY-P10652 hsBCL9CT-24
hsBCL9CT-24 is a Wnt/β-catenin (b-cat) pathway inhibitor with potent anti-tumor effect. hsBCL9CT-24 reactivates anti-cancer immune response suppressed by the oncogenic Wnt pathway and can be utilized for cancer research.
Wnt   β-catenin  
/
HY-N20600 Ternate buttercup root extract
Ternate buttercup root extract (Catclawbuttercup root extract) is a root extract of cat's claw herb (Ternate Buttercup) that can enhance immunity, reduce inflammation, scavenge free radicals, and has anti-cancer effects.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P3880 (D-Arg1,D-Pro2,D-Trp7,9,L-Leu11)-Substance P
(D-Arg1,D-Pro2,D-Trp7,9,L-Leu11)-Substance P is a neuropeptide Substance P (HY-P0201) antagonist.
Neurokinin Receptor  
Neurological, Eye or Ear Disease  
/
HY-B0667S Balsalazide-d3
Balsalazide-d3 is the deuterium labeled Balsalazide (HY-B0667). Balsalazide is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway.
Isotope-Labeled Compounds   STAT   Interleukin Related  
Cancer  
/
HY-18061R Ochromycinone (Standard)
Ochromycinone (Standard) ((Rac)-STA-21 (Standard)) is the analytical standard of Ochromycinone (HY-18061). This product is intended for research and analytical applications. Ochromycinone is a natural antibiotic and a STAT3 inhibitor. Ochromycinone can inhibits STAT3 DNA binding activity, STAT3 dimerization. Ochromycinone has anticancer and antimicrobial activity.
Reference Standards   Antibiotic   STAT   Bacterial  
Cancer   Infection  
/
HY-B1436S1 Nifuroxazide-13C6
Nifuroxazide-13C6 is the 13C6 labeled Nifuroxazide. Nifuroxazide is an effective inhibitor of STAT3, also exerts potent anti-tumor and anti-metastasis activity.
Isotope-Labeled Compounds   STAT   Bacterial   Antibiotic  
Cancer   Infection  
/
HY-P6422S LAVYQAGA-Arg(13C6,15N4) TFA
LAVYQAGA-Arg(13C6, 15N4) TFA is a peptide containing 13C6 and 15N4 labeled Arg.
Isotope-Labeled Compounds  
/
HY-P992036 Anti-CXCR2 Antibody
Anti-CXCR2 Antibody is an anti-CXCR2 antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

CXCR  
/
HY-169232 PCC16 chloride
PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers.
PROTACs   PD-1/PD-L1  
Cancer  
/
HY-P10715 Fmoc-KCRGDK
Fmoc-KCRGDK is a self-assembling peptide that can be used to prepare hydrogels and assist in drug delivery for immune checkpoint inhibitors. Fmoc-KCRGDK can be applied in cancer immunotherapy research.
Others  
Inflammation or Immune System Disease  
/
HY-B0180S1 Imiquimod-d9
Imiquimod-d9 is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
Isotope-Labeled Compounds   Toll-like Receptor (TLR)   Autophagy   SARS-CoV   HSV  
Infection   Inflammation or Immune System Disease  
/
HY-B0180S Imiquimod-d6
Imiquimod-d6 is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
Toll-like Receptor (TLR)   Autophagy   SARS-CoV   HSV  
Infection   Inflammation or Immune System Disease  
/
HY-P991309 ZM-008
ZM-008 is an anti-LLT1 monoclonal antibody. ZM-008 blocks the interaction between LLT1 and CD161 on the surface of NK cells and T cells. ZM-008 restores anti-tumor immune activity, shifts the tumor microenvironment to an immune-responsive state, and recovers NK cell-mediated cytotoxicity against tumor cells, thereby reversing immunosuppression in immune-resistant "cold" tumors. ZM-008 is applicable to the research of immune-resistant solid tumors.

Species: Human

C-type Lectin-like Receptors (CTLRs)  
Cancer  
/
HY-P10099 STAT3-IN-21, cell-permeable, negative control
STAT3-IN-21, cell-permeable, negative control, a peptide, is a negative control for Stat3 activity detection.
STAT  
Cancer  
/
HY-P5407 HD5
HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer.
SARS-CoV   Angiotensin-converting Enzyme (ACE)  
Colorectal Cancer   Small Cell Lung Cancer   Epithelial Ovarian Cancer   SARS-CoV-2 Infection   HPV Infection  
/
HY-N8098 Pulchinenoside E2
Pulchinenoside E2 is a triterpenoid saponin. Pulchinenoside E2 inhibits the phosphorylation of STAT3 and JAK2, blocks the nuclear translocation and transcriptional activity of STAT3, and suppresses STAT3-dependent mitochondrial oxidative phosphorylation. Pulchinenoside E2 inhibits invasion, migration and autophagy of triple-negative breast cancer cells. Pulchinenoside E2 can be used in research related to triple-negative breast cancer.
STAT   Autophagy   JAK  
Triple-Negative Breast Cancer  
/
HY-N6073R Soyasapogenol A (Standard)
Soyasapogenol A (Standard) is the analytical standard of Soyasapogenol A (HY-N6073). This product is intended for research and analytical applications. Soyasapogenol A is a triterpenoid aglycone of soyasaponins. Soyasapogenol A has activities such as anti-inflammation, anti-cancer, hepatoprotection and anti-HSV-1. Soyasapogenol A can be used in the research of tumors and immune inflammatory diseases.
Reference Standards   Apoptosis   HSV  
Cancer   Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P3448S Certepetide-13C6,15N2
Certepetide-13C6,15N2 (CEND-1-13C6,15N2) is the 13C- and 15N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
Isotope-Labeled Compounds   Integrin   Complement System  
/
HY-B1180R Vinburnine (Standard)
Vinburnine ((-)-Eburnamonine; (-)-Vincamone) (Standard) is the analytical standard of Vinburnine (HY-B1180). This product is intended for research and analytical applications. Vinburnine ((-)-Eburnamonine; (-)-Vincamone) phosphate is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.
Reference Standards   Apoptosis   p38 MAPK  
Melanoma  
/
HY-B0180S2 Imiquimod-d7
Imiquimod-d7 (R 837-d7) is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
Isotope-Labeled Compounds   HSV   Autophagy   Toll-like Receptor (TLR)   SARS-CoV  
Infection   Inflammation or Immune System Disease  
/
HY-P3448S1 Certepetide-13C2,15N
Certepetide-13C2,15N (CEND-1-13C2,15N) is the 13C- and 15N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
Isotope-Labeled Compounds   Integrin   Complement System  
/
HY-P6425S LCADMEDV-Arg(13C6,15N4) TFA
LCADMEDV-Arg(13C6, 15N4) TFA is a peptide containing 13C6 and 15N4 labeled Arg.
Isotope-Labeled Compounds  
/
HY-N19899 Phaeosphaeride A
Phaeosphaeride A is a STAT3 inhibitor with an IC50 of 0.61 mM against human STAT3. It exhibits higher selectivity for STAT3 over STAT1 and STAT5. Phaeosphaeride A inhibits the binding of STAT3 to DNA, STAT3-dependent transcriptional activity, as well as IL-6-induced phosphorylation and signaling of STAT3. Phaeosphaeride A activates the JNK, p38, Akt, CREB and STAT5A/B signaling pathways. Phaeosphaeride A induces oxidative stress (ROS), exerts antiproliferative and growth-inhibitory effects in cancer cells, and shows low cytotoxicity toward non-cancerous cells. Phaeosphaeride A is a phytotoxin and a weak animal toxin, with no antimicrobial activity against tested bacteria and fungi. Phaeosphaeride A can be used in research related to conditions such as cervical cancer and multiple myeloma, as well as weed infestations.

Source: Phaeosphaeria avenara

STAT   JNK   p38 MAPK   Akt   Reactive Oxygen Species (ROS)  
Cervical Cancer   Multiple Myeloma  
/
HY-12987S Pimozide-d4
Pimozide-d4 is a deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5.
Dopamine Receptor   Adrenergic Receptor   STAT  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-101407R Nicotinamide N-oxide (Standard)
Nicotinamide N-oxide (Standard) is the analytical standard of Nicotinamide N-oxide. This product is intended for research and analytical applications. Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the CXCR2 receptor.
Reference Standards   CXCR   Drug Metabolite   Endogenous Metabolite  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P991126 Ciltistotug
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P4116A pH-Low Insertion Peptide TFA
pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors.
Others  
Cancer   Metabolic or Endocrine Disease  
/
HY-P5407A HD5 TFA
HD5 TFA is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 TFA binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 TFA can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer.
SARS-CoV   Angiotensin-converting Enzyme (ACE)  
Colorectal Cancer   Small Cell Lung Cancer   Epithelial Ovarian Cancer   SARS-CoV-2 Infection   HPV Infection  
/
HY-B0497S1 Niclosamide-13C6
Niclosamide-13C6 is the 13C6 labeled Niclosamide. Niclosamide (BAY2353) is an orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. Niclosamide (BAY2353) inhibits STAT3 with IC50 of 0.25 μM in HeLa cells and inhibits DNA replication in a cell-free assay.
Isotope-Labeled Compounds   STAT   Parasite   Antibiotic  
Cancer   Infection  
/
HY-P10201 Ac-GpYLPQTV-NH2
Ac-GpYLPQTV-NH2 is a STAT3 inhibitor with an IC50 value of 0.33 μM. Ac-GpYLPQTV-NH2 has antitumor activity.
STAT  
Cancer  
/
HY-P1490 Bradykinin (2-9)
Bradykinin (2-9) is an amino-truncated Bradykinin peptide. Bradykinin (2-9) is a metabolite of Bradykinin, cleaved by Aminopeptidase P.
Bradykinin Receptor  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-14519S1 Methotrexate-d3 diammonium
Methotrexate-d3 diammonium is the deuterated-labeled Methotrexate (HY-14519). Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
Isotope-Labeled Compounds   Antifolate   Dihydrofolate reductase (DHFR)   NO Synthase   COX   Interleukin Related  
Breast Cancer   Arthritis   Systemic Lupus Erythematosus   Psoriasis   Lung Fibrosis  
/
HY-W654139 5'-Deoxy-5'-(methylthio)adenosine-d3
5'-Deoxy-5'-(methylthio)adenosine-d3 is deuterium labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
Isotope-Labeled Compounds   Apoptosis   Parasite   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-P990041 Firastotug
Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer.

Species: Human

CTLA-4  
Cancer   Inflammation or Immune System Disease  
/
HY-P990249 Anti-Mouse DR5/CD262 Antibody (MD5-1)
Anti-Mouse DR5/CD262 Antibody (MD5-1) is an anti-mouse DR5/CD262 IgG monoclonal antibody. Anti-Mouse DR5/CD262 Antibody (MD5-1) can eliminate myeloid derived suppressor cells (MDSCs) and enhance T cell anti-tumor immunity. Anti-Mouse DR5/CD262 Antibody (MD5-1) can be used for research on cancer such as gastric and colon cancer.

Species: Mouse

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-16938S 5'-Methylthioadenosine-13C6
5'-Methylthioadenosine-13C6 is the 13C-labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
Endogenous Metabolite   Apoptosis  
Metabolic or Endocrine Disease  
/
HY-113261S Oleoylcarnitine-d9
Oleoylcarnitine-d9 is deuterium labeled Oleoylcarnitine. Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation.
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease  
/
HY-P10114 STAT3-IN-24, cell-permeable
STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a STAT3 peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3.
STAT  
Cancer  
/
HY-N8389 Globulol
Globulol is a terpenoid metabolite and Antimicrobial agent. Globulol can be isolated from Alpinia oxyphylla Miq. Globulol binds to PAK4, reduces the expression level of PAK4 in cancer cells, decreases the phosphorylation of AKT, and downregulates the expressions of STAT3, phosphorylated STAT3, and PD-L1. Globulol promotes the secretion of CCL4 by cancer cells. Globulol reduces the viability and proliferation ability of cancer cells, induces G0/G1 cell cycle arrest and Apoptosis in cancer cells, and inhibits cancer cell migration and the integrity of 3D tumor spheres. Globulol enhances the relevant effects of anti-PD-1 agents in the cancer cell microenvironment. Globulol exhibits anticancer activity against liver cancer. Globulol inhibits the mycelial growth of phytopathogenic fungi and the growth of phytopathogenic bacteria. Globulol can be used in studies related to hepatocellular carcinoma.
Bacterial   Fungal   PAK   Akt   STAT   PD-1/PD-L1   Apoptosis   CCR  
Liver Cancer   Bacterial Infection   Fungal Infection  
/
HY-176785S MCB-294
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer.
Ras   Apoptosis   p38 MAPK   Caspase   TNF Receptor  
/
HY-P10115 APT STAT3
APT STAT3 is a specific STAT3-binding peptide. APT STAT3 can bind STAT3 with high specificity and affinity (～231 nmol/L). APT STAT3 is a tractable agent for translation to target the broad array of cancers harboring constitutively activated STAT3.
STAT  
Cancer  
/
HY-N6579 Arvenin I
Arvenin I is a natural cucurbitacin glucoside that activates T cells within the cancer-competitive environment. Arvenin I covalently reacts with and hyperactivates MKK3, thereby reviving the mitochondrial fitness of exhausted T cells through the activation of the p38MAPK pathway. Arvenin I exhibits broad-spectrum antiproliferative against cancer cells. Arvenin I enhances antitumor effects both as a monotherapy and in combination with immune checkpoint inhibitors in mice. Arvenin I can be used for cancer research, such as colon cancer, breast cancer, lung cancer, and ovarian cancer.
p38 MAPK   Mitochondrial Metabolism  
Cancer  
/
HY-P99825 Relfovetmab
Relfovetmab is a monoclonal antibody and also serves as a single-chain variable fragment component for engineering chimeric antigen receptors (CAR) in modified CAR-T cells. Relfovetmab can be used in studies of cancer and immune disorders.

Species: Feline

Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P10427A DV1 TFA
DV1 TFA is a CXCR4 inhibitor with anti-proteolytic properties that specifically blocks the binding of SDF-1α to its receptor. DV1 TFA inhibits the migration of breast cancer cells and enables the targeted delivery of avidin-PLGA nanoparticles to CXCR4-expressing cancer cells. DV1 TFA not only effectively suppresses the progression of metastatic breast cancer in mouse models, but also preferentially accumulates in brain tumor tissues rather than normal brain tissues, showing potential for inhibiting intracranial tumor metastasis. As a humoral immune stimulant, DV1 TFA induces the production of specific IgG, neutralizing antibodies and cellular immune responses, thereby providing the host with protection against lethal challenges. DV1 TFA has been applied to studies on CXCR4-expressing cancers, glioblastoma, dengue fever and other related diseases.
CXCR   Dengue Virus  
Infection  
/
HY-N14001 Naamidine J
Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors.

Source: Pericharax heteroraphis

TNF Receptor   Interleukin Related   Arginase   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-P990704 Rilvegostomig
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.

Species: Human

PD-1/PD-L1   Transmembrane Glycoprotein  
Non-Small Cell Lung Cancer   Endometrial Cancer  
/
HY-P10862 AH-D peptide
AH-D peptide is a brain-penetrant antiviral agent disrupting highly curved lipid membranes. AH-D peptide exhibits broad-spectrum antiviral activity against ZIKV, Dengue virus, Chikungunya virus, yellow fever virus and Japanese encephalitis virus, with
IC50
values of 11.9, 12.5, 35.7, 206 and 136 nM, respectively. AH-D peptide reduces the viral load in the brain, suppresses inflammation, protects neurons, and does not damage the blood brain barrier. AH-D peptide restores antitumor immunity by decreasing circulating PD-L1+ exosomes, reducing intratumoral immunosuppressive cells (regulatory T cells, myeloid-derived suppressor cells), and enhancing T cell function. AH-D peptide inhibits membrane-enveloped viruses and cancer cell metastasis in vivo. AH-D peptide exhibits no immunogenicity and has negligible effects on normal tissues. AH-D peptide can be used for research in Zika virus and other mosquito-borne viruses, cancer immunotherapy and metastasis.
Exosomes   Virus Protease  
Cancer   Infection  
/
HY-N3387 Licoricidin
Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC50=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer. Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect. Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo. Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations.
Apoptosis   NF-κB   Akt   MMP  
Cancer   Inflammation or Immune System Disease  
/
HY-P991122 Besufetamig
Besufetamig is a bispecific antibody targeting programmed cell death 1 (PD-1) and CD3ε chain. Besufetamig modulates the activity of immune cells, exerting immunosuppressive and antineoplastic activities. Besufetamig is promising for research of cancers.

Species: Human

PD-1/PD-L1   CD3  
Cancer   Inflammation or Immune System Disease  
/
HY-P10449 M2 Peptide
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P10424 OPBP-1
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research.
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-148748G Butyzamide (GMP)
Butyzamide (GMP) is Butyzamide (HY-148748) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay.
JAK   STAT   p38 MAPK  
Blood or Cardio-cerebrovascular Disease  
/
HY-103544 [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, a Substance P derivative, is a biased agonist toward neuropeptide and chemokine receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P activates G12. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P binds to IL-8 and GRP receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P inhibits ERK-2 activation, activates JNK activity. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P stimulates an increase in neutrophil migration and Ca2+ mobilization. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is also a bombesin antagonist, and inhibits the growth of small cell lung cancer
JNK   Bombesin Receptor   Interleukin Related  
Digestive System Disease   Lung Cancer   Pain   Digestive System Inflammation  
/
HY-N6073 Soyasapogenol A
Soyasapogenol A is a triterpenoid aglycone of soyasaponins. Soyasapogenol A has activities such as anti-inflammation, anti-cancer, hepatoprotection and anti-HSV-1. Soyasapogenol A can be used in the research of tumors and immune inflammatory diseases.
Apoptosis   HSV  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Viral Infection   Digestive System Inflammation  
/
HY-14519S Methotrexate-d3
Methotrexate-d3 is the deuterated-labeled Methotrexate (HY-14519). Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
Isotope-Labeled Compounds   Antifolate   Dihydrofolate reductase (DHFR)   NO Synthase   COX   Interleukin Related  
Breast Cancer   Arthritis   Systemic Lupus Erythematosus   Psoriasis   Lung Fibrosis  
/
HY-P991196 Anti-CD24 Antibody (SWA11)
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody targeting CD24, with high affinity and specificity for CD24-expressing tumor cells. Anti-CD24 Antibody (SWA11) triggers endocytosis, alters STAT3-dependent gene expression, regulates Src phosphorylation, and blocks CD24-mediated signaling pathways. Anti-CD24 Antibody (SWA11) is applicable to cancer-related research such as lung cancer and ovarian cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Transmembrane Glycoprotein  
Lung Cancer   Ovarian Cancer  
/
HY-P99484 Botensilimab
Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer.

Species: Human

CTLA-4  
Non-Small Cell Lung Cancer  
/
HY-N10472 STAT3-IN-14
STAT3-IN-14 (Compound 1) is a STAT3 inhibitor and has STAT3 phosphorylation inhibitory activity. STAT3-IN-14 (Compound 1) can directly bind to the hinge region of STAT3.
STAT  
Cancer  
/
HY-P11303 PADRE peptide
PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4+ T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8+ T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer.
CD74   MHC  
Cervical Cancer   Glioblastoma  
/
HY-P99917 Eflepedocokin alfa
Eflepedocokin alfa is a recombinant fusion protein. Eflepedocokin alfa consists of human IL-22 fused to human IgG2-Fc domain. Eflepedocokin alfa leads to the activation of IL-22/IL-22R-mediated signal transduction pathways as well as STAT3. Eflepedocokin alfa plays a role in immune response and bacterial infection, enhancing intestinal barrier function, intestinal immunity, and tissue repair.

Species: Human

STAT  
Infection   Inflammation or Immune System Disease  
/
HY-W251598S Bicarbonate-13C sodium
Bicarbonate-13C sodium is the 13C-labeled Sodium bicarbonate (HY-Y0756). Sodium bicarbonate is an inorganic salt that is neutral to slightly alkaline and easily decomposes when exposed to moisture in the air. Sodium bicarbonate can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, medicine, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
Reference Standards   Bacterial   NO Synthase  
Cancer   Gastric Disease  
/
HY-P990651 PY314
PY314 is a humanized antibody targeting TREM2. PY314 binds TREM2 on tumor-associated macrophages, depletes TREM2-high tumor-associated macrophages, reduces pro-tumorigenic M2 macrophage infiltration, increases CD8+ T cell, NK cell, and M1 macrophage infiltration, creates a proinflammatory tumor microenvironment, and promotes antitumor immune responseS. PY314 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, breast cancer, and advanced refractory solid tumors.

Species: Human

TREM receptor  
Ovarian Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer  
/
HY-P990961 Palverafusp alfa
Palverafusp alfa (IMM-2510; SYN-2510) is a PD-L1/VEGF-targeting IgG1κ type humanized antibody. Palverafusp alfa blocks PD-1/PD-L1 binding, relieves immune suppression, mediates PD-L1-directed antibody-dependent cellular cytotoxicity (ADCC). Palverafusp alfa blocks VEGF/VEGFR binding, inhibits angiogenic signaling, relieves VEGF-induced immune suppression. Palverafusp alfa reduces endothelial cell proliferation, enhances ADCC and antibody-dependent cellular phagocytosis (ADCP), inhibits tumor growth, reverses T cell immune suppression. Palverafusp alfa exhibits immune stimulatory, antiangiogenic, and anti-tumor activity in the tumor microenvironment. Palverafusp alfa can be used for the research of cancer, such as solid tumors, non-small cell lung cancer.

Species: Human

VEGFR   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P990042 Gotistobart
Gotistobart (ONC-392; BNT 316) is a humanized anti-CTLA-4 antibody with selective regulatory T cell depletion activity in the tumor microenvironment. Gotistobart can be used for the research of cancer, such as non-small cell lung cancer.

Species: Human

CTLA-4  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
/
HY-P990294 Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)
Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is an anti-mouse CD106/VCAM-1 IgG1 monoclonal antibody. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) reduces inflammatory response and oxidative stress by lowering p-STAT3 and reactive oxygen species (ROS) levels. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can alleviate cardiac inflammation and fibrosis by reducing the expression of collagen I and collagen III. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can be used for research on cardiovascular conditions such as hypertensive heart condition and subretinal fibrosis.

Species: Mouse

Transmembrane Glycoprotein   STAT   Collagen   Reactive Oxygen Species (ROS)   Interleukin Related  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P991487 LASN01
LASN01 is a humanized antibody targeting IL-11R, with a Kd of 37 pM. LASN01 blocks the IL-11 signaling pathway via IL-11Rα, and inhibits the phosphorylation of STAT3 and ERK, as well as the expression of pro-inflammatory cytokines, hyaluronic acid, procollagen and fibrotic markers. LASN01 can be used in studies related to thyroid eye disease.

Species: Human

/
HY-P10131 3BP-3940
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases.
Radionuclide-Drug Conjugates (RDCs)   FAP  
Cancer  
/
HY-P4116 pH-Low Insertion Peptide
pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors.
Others  
Cancer   Metabolic or Endocrine Disease  
/
HY-W251598B Sodium bicarbonate, for molecular biology
Sodium bicarbonate, for molecular biology (Sodium hydrogen carbonate for molecular biolog; Soda bicarbonate for molecular biolog) is an inorganic salt. Sodium bicarbonate can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
Bacterial   NO Synthase  
Cancer   Gastric Disease  
/
HY-113573 Protosappanin A
Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses JAK2/STAT3-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3.
Interleukin Related   JAK   STAT  
Lung Cancer   Pancreatic Cancer   Pain   Autoimmune Disease   Digestive System Inflammation  
/
HY-P99757 Nivatrotamab
Nivatrotamab (Hu3F8-BsAb) is a bispecific antibody targeting GD2 and CD3, with KD values of 5.8 nM and 194 nM, respectively. Nivatrotamab redirects T cells to tumor sites and activates immune synapses, thereby mediating antibody-dependent T cell-mediated cytotoxicity. Nivatrotamab induces specific tumor cytotoxicity, stimulates the release of Th1 cytokines and promotes immune cell infiltration into tumors. In addition, its Fc segment deglycosylation design effectively prevents complement activation and cytokine storm. Nivatrotamab can be widely used in research related to various solid tumors, including melanoma, neuroblastoma, osteosarcoma, small cell lung cancer, breast cancer, Ewing's sarcoma, colon cancer, ovarian cancer and rhabdomyosarcoma.

Species: Human

CD3  
Cancer  
/
HY-107202GL Polyinosinic-polycytidylic acid (GMP Like)
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Inflammation or Immune System Disease  
/
HY-P99118 Serplulimab
Serplulimab (HLX 10) is a humanized anti-PD-1 monoclonal antibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer.

Species: Human

PD-1/PD-L1   Akt   STAT  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer  
/
HY-P9916 Sarilumab
Sarilumab is a monoclonal antibody targeting IL6 that binds to IL6R and blocks the binding of IL6, thereby inhibiting the activation of the downstream STAT3 phosphorylation signaling pathway. In tumor cells with active IL6/STAT3 signaling pathways, Sarilumab induces Apoptosis and inhibits cell growth. Sarilumab is applicable to research related to prostate cancer, lung cancer and rheumatoid arthritis.

Species: Human

Interleukin Related   STAT   Apoptosis  
Lung Cancer   Prostate Cancer   Rheumatoid Arthritis  
/
HY-P6292A KS-133 TFA
KS-133 TFA is a highly selective and potent antagonist of the vascular active enteropeptide receptor 2 (VIPR2) with IC50 values for Ca influx measurement and cAMP measurement of 24.8 nM and 500 nM, respectively. KS-133 TFA reverses the tumor-promoting M2 phenotype of tumor-associated macrophages to the anti-tumor M1 phenotype, alters the tumor immune microenvironment, and inhibits tumor growth. KS-133 TFA can be used for research on schizophrenia and cancer immune regulation.
PACAP Receptor  
Cancer   Neurological, Eye or Ear Disease   Immunomodulation  
/
HY-P99244 Fezakinumab
Fezakinumab (ILV 094) is an anti-IL-22 monoclonal antibody. Fezakinumab inhibits IL-22 signal transduction, and regulates the JAK1/STAT3 pathway as well as apoptotic proteins. Fezakinumab alleviates airway remodeling, alveolar enlargement and inflammatory cell infiltration in lung tissues. Fezakinumab reduces the levels of neutrophils, lymphocytes, eosinophils and macrophages in lung tissues. Fezakinumab can be used in the research of chronic obstructive pulmonary disease and skin diseases.

Species: Human

Interleukin Related   JAK   STAT   Caspase   Bcl-2 Family  
Autoimmune Disease  
/
HY-P99046 Selicrelumab
Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study.

Species: Human

TNF Receptor  
Colorectal Cancer   Metastatic Breast Cancer   Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Pancreatic Ductal Adenocarcinoma  
/
HY-P5005 VIPhyb
VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate PD1. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis.
CMV   PD-1/PD-L1  
Inflammation or Immune System Disease  
/
HY-W251598C Sodium bicarbonate, for cell culture
Sodium bicarbonate, for cell culture (Sodium hydrogen carbonate for cell culture; Soda bicarbonate for cell culture) is an inorganic salt that is neutral to slightly alkaline and easily decomposes when exposed to moisture in the air. Sodium bicarbonate, for cell culture can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, medicine, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
Environmental Pollutants   Bacterial  
Gastric Disease   Triple-Negative Breast Cancer  
/
HY-P991097 Pumitamig
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.

Species: Human

VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P701098 STAT3 Protein, Human (Full Length, His)
STAT3 is a signal transducer and transcriptional activator that coordinates diverse cellular processes in response to growth factors and cytokines such as interleukin-6 and KITLG/SCF. Upon activation, STAT3 recruits coactivators to target gene promoters, thereby affecting proliferation, differentiation, and immune responses. STAT3 Protein, Human (Full Length, His) is the recombinant human-derived STAT3 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P70574 STAT3 Protein, Human (His)
STAT3 is a signal transducer and transcriptional activator that coordinates diverse cellular processes in response to growth factors and cytokines such as interleukin-6 and KITLG/SCF. Upon activation, STAT3 recruits coactivators to target gene promoters, thereby affecting proliferation, differentiation, and immune responses. STAT3 Protein, Human (His) is the recombinant human-derived STAT3 protein, expressed by E. coli , with C-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P700536 CXCR2 Protein, Human (His-SUMO)
CXCR2, the receptor for interleukin-8 (IL-8), orchestrates neutrophil activation through a G-protein-mediated phosphatidylinositol-calcium second messenger system upon IL-8 binding. Exhibiting high-affinity binding to IL-8, CXCR2 also interacts with other ligands like CXCL3, GRO/MGSA, and NAP-2. The involvement of GNAI2 underscores the intricate signaling mechanisms regulating neutrophil function through CXCR2. CXCR2 Protein, Human (His-SUMO) is the recombinant human-derived CXCR2 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

Species: Human; Source: E. coli

Cytokines and Growth Factors Receptor Proteins Chemokine & Receptors G-Protein-Coupled Receptors (GPCRs) CXC Chemokine Receptor Chemokine Receptor CXCR2

/
HY-P71369 TINAGL1 Protein, Human (HEK293, His)
TINAGL1 Protein, implicated in adrenocortical zonation, may regulate distinct adrenal cortex zones and repress CYP11B1 gene expression in adrenocortical cells. As a member of the non-catalytic peptidase C1 family, its distinctive function does not involve enzymatic activity. Unraveling TINAGL1's molecular pathways could offer insights into its role in adrenal physiology, shedding light on its potential to manipulate adrenal function. TINAGL1 Protein, Human (HEK293, His) is the recombinant human-derived TINAGL1 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Human; Source: HEK293

/
HY-P790083 CXCR2 Protein, Human (Cell-Free, His)
CXCR2, the receptor for interleukin-8 (IL-8), orchestrates neutrophil activation through a G-protein-mediated phosphatidylinositol-calcium second messenger system upon IL-8 binding. Exhibiting high-affinity binding to IL-8, CXCR2 also interacts with other ligands like CXCL3, GRO/MGSA, and NAP-2. The involvement of GNAI2 underscores the intricate signaling mechanisms regulating neutrophil function through CXCR2. CXCR2 Protein, Human (Cell-Free, His) is the recombinant human-derived CXCR2, expressed by E. coli Cell-free, with N-10*His labeled tag. The total length of CXCR2 Protein, Human (Cell-Free, His) is 360 a.a..

Species: Human; Source: E. coli Cell-free

Cytokines and Growth Factors Chemokine & Receptors CXC Chemokine Receptor CXCR2

/
HY-P702257 CXCR2 Protein, Mouse (Cell-Free, His)
CXCR2 protein acts as a receptor for interleukin-8 and induces neutrophil activation through the G protein-mediated phosphatidylinositol-calcium second messenger system. In addition to IL-8, CXCR2 also exhibits high-affinity binding to ligands such as CXCL3, GRO/MGSA, and NAP-2. CXCR2 Protein, Mouse (Cell-Free, His) is the recombinant mouse-derived CXCR2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

Species: Mouse; Source: E. coli Cell-free

Cytokines and Growth Factors Receptor Proteins Chemokine & Receptors G-Protein-Coupled Receptors (GPCRs) Cytokine Receptors CXC Chemokine Receptor Chemokine Receptor CXCR2

/
HY-P7541 Arginase-1/ARG1 Protein, Human (C-His)
Arginase-1 Protein, Human (C-His) expresses in E. coli with a His tag at the C-terminus. Arginase-1 Protein inhibits the growth of the arginine-depleting enzyme arginine deiminase (ADI)-resistant Hep3B tumor cells in mice.

Species: Human; Source: E. coli

Enzymes & Regulators Hydrolases (EC 3)

/
HY-P7602 Arginase-1/ARG1 Protein, Human (HEK293, His)
Arginase-1 Protein, Human (HEK293, His) expresses in HEK293 cells with a His tag at the C-terminus. Arginase-1 Protein inhibits the growth of the arginine-depleting enzyme arginine deiminase (ADI)-resistant Hep3B tumor cells in mice.

Species: Human; Source: HEK293

Enzymes & Regulators Hydrolases (EC 3)

/
HY-P704899 STAT3 Protein, Human (562a.a, His)

Species: Human; Source: E. coli

/
HY-P80282 Phospho-STAT3 (Tyr705) Antibody (YA146)
Phospho-STAT3 (Tyr705) Antibody (YA146) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-STAT3 (Tyr705).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P86409 Arginase-1 Antibody (YA6101)
Arginase-1 Antibody (YA6101) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Arginase-1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80019 Arginase-1 Antibody (YA613)
Arginase-1 Antibody (YA613) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Arginase-1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P87793 HIF-1α Antibody (YA7478)
HIF-1α Antibody (YA7478) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to HIF-1α.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81158 CXCR2 Antibody
CXCR2 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to CXCR2.

Host: Rabbit; Reactivity: Human

Polyclonal Antibodies Primary Antibodies

/
HY-P84300 STAT3 Antibody (YA3997)
STAT3 Antibody (YA3997) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to STAT3.

Host: Mouse; Reactivity: Human, Mouse, Monkey

Monoclonal Antibodies Primary Antibodies

/
HY-P87666 Phospho-STAT3 (Tyr705) Antibody (YA7351)
Phospho-STAT3 (Tyr705) Antibody (YA7351) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Phospho-STAT3 (Tyr705).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P84207 CXCR2 Antibody (YA3904)
CXCR2 Antibody (YA3904) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CXCR2.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84207A CXCR2 Antibody (YA3904)(PBS only)
CXCR2 Antibody (YA3904) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CXCR2.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P80902A STAT3 Antibody (YA666)(PBS only)
STAT3 Antibody (YA666)(PBS only) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to STAT3.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P84300A STAT3 Antibody (YA3997)(PBS only)
STAT3 Antibody (YA3997) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to STAT3.

Host: Mouse; Reactivity: Human, Mouse, Monkey

Monoclonal Antibodies Primary Antibodies

/
HY-P86382 STAT3 Antibody (YA6074)
STAT3 Antibody (YA6074) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to STAT3.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-K2034 OptiLNP Antibody-ctLNP RNA Transfection Reagent (Human Primary T Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology and is specifically optimized for human primary T cells. It enables efficient and targeted RNA delivery, improving transfection efficiency in difficult-to-transfect primary T cells. The kit is ideally suited for applications including CAR-T and TCR-T cell engineering, cancer immunology research, immune cell engineering, and in vitro T cell functional studies.

Cell Biology Cell Culture Cell Transfection

/

References

[1]. Gabrilovich DI, et al. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-174.  [Content Brief]

[2]. Bronte V, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.  [Content Brief]

[3]. Veglia F, et al. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108-119.  [Content Brief]

[4]. Kumar V, et al. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208-220.  [Content Brief]

[5]. Vasquez-Dunddel D, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123(4):1580-1589.  [Content Brief]

[6]. Corzo CA, et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439-2453.  [Content Brief]

[7]. Waight JD, et al. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest. 2013;123(10):4464-4478.  [Content Brief]

[8]. Highfill SL, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6(237):237ra67.  [Content Brief]

[9]. Long AH, et al. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol Res. 2016;4(10):869-880.  [Content Brief]

[10]. Orillion A, et al. Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine tumor models. Clin Cancer Res. 2017;23(17):5187-5201.  [Content Brief]

Keywords

MDSCs | myeloid-derived suppressor cells | cancer immunity | tumor microenvironment | immunotherapy resistance | immune checkpoint blockade | CXCR2 | STAT3 | ARG1 | HIF-1αα